Investor Expectations to Drive Momentum within Mosaic, Baker Hughes, Acelrx Pharma, Ciena, Exelon, and SM Energy – Discovering Underlying Factors of Influence

November 6, 2017 7:30 AM

NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Mosaic Company (NYSE: MOS), Baker Hughes Incorporated (NYSE: BHGE), Acelrx Pharmaceuticals, Inc. (NASDAQ: ACRX), Ciena Corporation (NYSE: CIEN), Exelon Corporation (NYSE: EXC), and SM Energy Company (NYSE: SM) including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MOS DOWNLOAD: http://Fundamental-Markets.com/register/?so=MOS

BHGE DOWNLOAD: http://Fundamental-Markets.com/register/?so=BHGE

ACRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACRX

CIEN DOWNLOAD: http://Fundamental-Markets.com/register/?so=CIEN

EXC DOWNLOAD: http://Fundamental-Markets.com/register/?so=EXC

SM DOWNLOAD: http://Fundamental-Markets.com/register/?so=SM

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine The Mosaic Company (NYSE: MOS), Baker Hughes Incorporated (NYSE: BHGE), Acelrx Pharmaceuticals, Inc. (NASDAQ: ACRX), Ciena Corporation (NYSE: CIEN), Exelon Corporation (NYSE: EXC), and SM Energy Company (NYSE: SM) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. All information in this release was accessed November 5, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All amounts in millions (except per share amounts).

-----------------------------------------

THE MOSAIC COMPANY (MOS) REPORT OVERVIEW

Mosaic's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Mosaic reported revenue of $1,754.6 vs $1,674.6 (up 4.8%), diluted earnings per share $0.28 vs -$0.03. For the twelve months ended December 31, 2016 vs December 31, 2015, Mosaic reported revenue of $7,162.8 vs $8,895.3 (down 19.5%), diluted earnings per share $0.85 vs $2.78 (down 69.4%).

To read the full The Mosaic Company (MOS) report, download it here: http://Fundamental-Markets.com/register/?so=MOS

-----------------------------------------

BAKER HUGHES INCORPORATED (BHGE) REPORT OVERVIEW

Baker Hughes's Recent Financial Performance

For the three months ended September 30, 2017 vs September 30, 2016, Baker Hughes reported revenue of $5,375 vs $3,024 (up 77.7%), diluted earnings per share -$0.10 vs -$0.31. For the twelve months ended December 31, 2016 vs December 31, 2015, Baker Hughes reported revenue of $9,841 vs $15,742 (down 37.5%), diluted earnings per share -$6.31 vs -$4.49.

To read the full Baker Hughes Incorporated (BHGE) report, download it here: http://Fundamental-Markets.com/register/?so=BHGE

-----------------------------------------

ACELRX PHARMACEUTICALS, INC. (ACRX) REPORT OVERVIEW

Acelrx Pharma's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, Acelrx Pharma reported revenue of $2.66 vs $4.53 (down 41.3%), diluted earnings per share -$0.29 vs -$0.24. For the twelve months ended December 31, 2016 vs December 31, 2015, Acelrx Pharma reported revenue of $17.36 vs $19.26 (down 9.9%), diluted earnings per share -$0.95 vs -$0.60. Acelrx Pharma is expected to report earnings on 11/09/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is -$0.26. The reported EPS for the same quarter last year was -$0.25.

To read the full Acelrx Pharmaceuticals, Inc. (ACRX) report, download it here: http://Fundamental-Markets.com/register/?so=ACRX

-----------------------------------------

CIENA CORPORATION (CIEN) REPORT OVERVIEW

Ciena's Recent Financial Performance

For the three months ended July 31, 2017 vs July 31, 2015, Ciena reported revenue of $728.7 vs $670.6 (up 8.7%), diluted earnings per share $0.39 vs $0.23 (up 69.6%). For the twelve months ended October 31, 2016 vs October 31, 2015, Ciena reported revenue of $2,600.6 vs $2,445.7 (up 6.3%), diluted earnings per share $0.51 vs $0.10 (up 410.0%). Ciena is expected to report earnings on 12/14/2017. The report will be for the fiscal Quarter ending October 2017. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $0.44. The reported EPS for the same quarter last year was $0.38.

To read the full Ciena Corporation (CIEN) report, download it here: http://Fundamental-Markets.com/register/?so=CIEN

-----------------------------------------

EXELON CORPORATION (EXC) REPORT OVERVIEW

Exelon's Recent Financial Performance

For the three months ended September 30, 2017 vs September 30, 2016, Exelon reported revenue of $8,769 vs $9,002 (down 2.6%), diluted earnings per share $0.85 vs $0.53 (up 60.4%), and dividends per share $0.33 vs $0.32 (up 3.1%). For the twelve months ended December 31, 2016 vs December 31, 2015, Exelon reported revenue of $31,360 vs $29,447 (up 6.5%), diluted earnings per share $1.22 vs $2.54 (down 52.0%), and dividends per share $1.26 vs $1.24 (up 1.6%).

To read the full Exelon Corporation (EXC) report, download it here: http://Fundamental-Markets.com/register/?so=EXC

-----------------------------------------

SM ENERGY COMPANY (SM) REPORT OVERVIEW

SM Energy's Recent Financial Performance

For the three months ended June 30, 2017 vs June 30, 2016, SM Energy reported revenue of $120.7 vs $341.8 (down 64.7%), diluted earnings per share -$1.08 vs -$2.48. For the twelve months ended December 31, 2016 vs December 31, 2015, SM Energy reported revenue of $1,217.5 vs $1,557.0 (down 21.8%), diluted earnings per share -$9.90 vs -$6.61.

To read the full SM Energy Company (SM) report, download it here: http://Fundamental-Markets.com/register/?so=SM

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@fundamental-markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: andrew.duffie@fundamental-markets.com

© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@fundamental-markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Source: Fundamental Markets

Categories

Press Releases